During the past decade, Profil Institut für stoffwechselforschung GmbH conducted 64 clinical trials. In the 10-year time frame, 64 clinical trials started and 6 clinical trials were completed, i.e. on average, 9.4% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 6 clinical trials were completed. i.e. 24% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Profil Institut für stoffwechselforschung GmbH" #1 sponsor was "Adocia" with 22 trials, followed by "Profil Institut für Stoffwechselforschung GmbH" with 21 trials sponsored, "Eli Lilly and Company" with 11 trials sponsored, "Zealand Pharma" with 9 trials sponsored and "Gan and Lee Pharmaceuticals, USA" with 9 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Profil Institut für stoffwechselforschung GmbH" #1 collaborator was "Profil Institut für Stoffwechselforschung GmbH" with 8 trials as a collaborator, "Eli Lilly and Company" with 6 trials as a collaborator, "Sanofi" with 4 trials as a collaborator, "Tonghua Dongbao Pharmaceutical Co.,Ltd" with 3 trials as a collaborator and "Medical University of Graz" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Profil Institut für stoffwechselforschung GmbH" are "Diabetes Mellitus" (14 trials), "Type 1 Diabetes Mellitus" (11 trials), "Type 2 Diabetes Mellitus" (9 trials), "Diabetes Mellitus, Type 1" (8 trials) and "Diabetes Mellitus, Type 2" (7 trials). Many other conditions were trialed in "Profil Institut für stoffwechselforschung GmbH" in a lesser frequency.

Most popular intervention types in "Profil Institut für stoffwechselforschung GmbH" are "Drug" (73 trials), "Device" (7 trials), "Other" (6 trials), "Procedure" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Humalog®" (10 trials), "BioChaperone insulin lispro" (4 trials), "Insulin Lispro" (4 trials) and "Euglycemic clamp with BC Combo THDB0207" (3 trials). Other intervention names were less common.

The vast majority of trials in "Profil Institut für stoffwechselforschung GmbH" are 71 trials for "All" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Profil Institut für stoffwechselforschung GmbH". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 75 completed trials in Profil Institut für stoffwechselforschung GmbH, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Profil Institut für stoffwechselforschung GmbH, 59 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 4 trials that are defined as “Not Applicable".